ReproCell

ReproCell Profit per Employee

The Profit per Employee of ReproCell (4978.T) as of Oct 27, 2026 is -5.33 M JPY. In the previous year, Profit per Employee was 930,135.14 JPY — a change of -673.10% (lower).

Profit per Employee

-5.33 MJPY

YoY

-673.10%

Last updated:

Profit per Employee of ReproCell is 2026 -5.33 M JPY. Profit per Employee of ReproCell was 2025 930,135.14 JPY. It decreases by -673.10% lower compared to the previous year.

The ReproCell Profit per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Profit per Employee
Date
Profit per Employee
Jan 1, 2019
-5.42 M JPY
Jan 1, 2020
-9.16 M JPY
Jan 1, 2021
-7.32 M JPY
Jan 1, 2022
-5.18 M JPY
Jan 1, 2023
-2.75 M JPY
Jan 1, 2024
-283,018.02 JPY
Jan 1, 2025
930,135.14 JPY
Jan 1, 2026
-5.33 M JPY
The ReproCell Profit per Employee history
YEARProfit per EmployeeYoY
-5.33 MJPY-673.10%
930,135.14JPY-428.65%
-283,018.02JPY-89.71%
-2.75 MJPY-46.91%
-5.18 MJPY-29.23%
-7.32 MJPY-20.06%
-9.16 MJPY+69.02%
-5.42 MJPY-72.31%
-19.57 MJPY+138.25%
-8.21 MJPY-53.52%
-17.67 MJPY+334.13%
-4.07 MJPY+237.35%
-1.21 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Profit per Employee of ReproCell is -5.33 M JPY in 2026.

Profit per Employee of ReproCell changed from 930,135.14 JPY to -5.33 M JPY, representing a -673.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Profit per Employee ReproCell since 2006 – with annual values, charts, and detailed analysis.

Profit per employee measures how much net income each employee generates on average. It is a key indicator of workforce efficiency.

Profit per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Profit per Employee's ReproCell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — ReproCell

All Key Metrics — ReproCell